Search Results
Mar 23, 2026, 07:00 ET BioLineRx Reports 2025 Financial Results and Provides Corporate Update
NCT05618301) evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD) was presented at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition
More news about: BioLineRx Ltd.
Mar 16, 2026, 06:30 ET Eminent Signs Drill Contract for 10,000m RC Drill Program at HSRP
reporting.This upcoming drill campaign builds on encouraging results from prior exploration, including a new discovery diamond drill intercept in hole HSC005 of 9.2 meters grading 3.2 g/t Au (fire assay total gold), as previously reported (news release dated
More news about: Eminent Gold Corp.
Jan 21, 2026, 07:30 ET Eminent Appoints Ivan Bebek as Strategic Advisor for Corporate Development and Finance
releases dated June 19, 2025 (earlier intercepts along the Otis fault structure, e.g., 7.9 m @ 1.2 g/t Au in HSC004 and other significant gold mineralization in HSC002–HSC004) and January 6, 2026 (hole HSC005 at the Otis target within the Hot Springs Range Project: 9.2 meters grading 3.2 g/t Au from 295.5 m
More news about: Eminent Gold Corp.
Jan 13, 2026, 11:34 ET Study Reveals Method to Restore 'Exhausted' Blood Stem Cells
different levels of stress and compared their function and molecular makeup."This was done in mice, but in a way, we were able to compare how HSC metabolic functions changed between a 20-year-old, a 40-year-old, and an 80-year-old," Filippi says.They report three key findings:The
More news about: Cincinnati Children's Hospital Medical Center
Jan 08, 2026, 10:30 ET Hanwha and HavocAI Formalize Partnership to Develop 200-Foot Autonomous Surface Vessel
ARLINGTON, Va., Jan. 8, 2026 /PRNewswire/ -- On Thursday, Hanwha Defense USA (HDUSA), Hanwha Systems Co (HSC), and U.S.-based collaborative autonomy company HavocAI announced they will jointly develop 200-foot autonomous surface vessels (ASV). This agreement
More news about: Hanwha Defense USA
Jan 06, 2026, 12:03 ET Espervita's EVT0185 Demonstrates Reversal of Metabolic Dysfunction and Liver Fibrosis in Cell Metabolism Publication
limitation of prior metabolic therapies.Reversal of hepatic fibrosis by 38%.Direct inhibition of HSC activation.Efficacy in human liver slices and primary human HSCs, confirming dual metabolic and antifibrotic activity, supporting
More news about: Espervita Therapeutics, Inc.
Jan 06, 2026, 07:30 ET Eminent Intercepts 9.2m @ 3.2 g/t Au and Appoints Dan McCoy as President and CEO
- Eminent Gold Corp. (TSXV: EMNT) (OTCQB: EMGDF) (FSE: 7AB) ("Eminent" or the "Company") is pleased to announce the assay results of Drillhole HSC005 from its Otis target at its 100% owned Hot Springs Range Project ("HSRP") located just ~15 km northwest of the prolific Getchell Trend1 (Figure
More news about: Eminent Gold Corp.
Dec 22, 2025, 04:44 ET Bybit's Yoyee Wang Says Capital-Efficient Custody and Regulatory Clarity Are Key to Institutional Crypto Adoption
second-largest cryptocurrency exchange by trading volume, participated in the HSC Asset Management high-level conference in Abu Dhabi, where Yoyee Wang, Head of Business-to-Business (BBU), highlighted the role of custody
More news about: Bybit
Dec 22, 2025, 04:38 ET Bybit's Yoyee Wang Says Capital-Efficient Custody and Regulatory Clarity Are Key to Institutional Crypto Adoption
cryptocurrency exchange by trading volume, participated in the HSC Asset Management high-level conference in Abu Dhabi, where Yoyee Wang, Head of Business-to-Business (BBU), highlighted the role of custody
More news about: Bybit
Nov 24, 2025, 07:00 ET BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
NCT05618301) evaluating motixafortide as monotherapy and in combination with natalizumab for CD34+ hematopoietic stem cell (HSC) mobilization for gene therapies in sickle cell disease (SCD) was accepted for presentation at the 67th American Society of Hematology (ASH) Annual Meeting
More news about: BioLineRx Ltd.
Nov 21, 2025, 10:31 ET Patient-Derived Xenograft/PDX Model Market worth US$0.66 billion by 2030 with 12.5% CAGR | MarketsandMarkets™
tumor-model databases and standardized study packages (including subcutaneous, orthotopic, and I/O readouts). CRL also validates humanized-immune PDx (HSC/PBMC) to run checkpoint/bispecific and cell-therapy studies, which is a key differentiator as sponsors shift to immuno-oncology combinations. Strategically,
More news about: MarketsandMarkets
Nov 13, 2025, 11:00 ET Marelli awarded for its new front axle for electric racing vehicles at the Professional MotorSport World Expo 2025
competitions in the coming years. Among the latest innovations presented are the new e-axle "Race E-volution 500" and the debut of the new high-speed camera "HSC-130", alongside advanced technologies for two-wheel and four-wheel competitions. Awarded in the 'Powertrain technology of the
More news about: Marelli
Nov 12, 2025, 09:30 ET Rely Home Receives Investment from H.I.G. Capital
independent, affiliated technicians under its three brands: Choice Home Warranty ("CHW"), Home Warranty of America ("HWA"), and Home Service Club ("HSC"). Victor Hakim, Founder and Chairman of Rely, said, "We are excited to partner with H.I.G. and believe that with their strategic
More news about: Rely Home, Inc.
Nov 12, 2025, 09:30 ET H.I.G. Capital Invests in Rely Home
independent, affiliated technicians under its three brands: Choice Home Warranty ("CHW"), Home Warranty of America ("HWA"), and Home Service Club ("HSC"). Victor Hakim, Founder and Chairman of Rely, said, "We are excited to partner with H.I.G. and believe that with their strategic
More news about: H.I.G. Capital
Nov 07, 2025, 17:00 ET Lunai Bioworks schafft es, sowohl primäre als auch metastasierte Bauchspeicheldrüsentumoren in präklinischen humanisierten Modellen komplett zurückzubilden, was einen Durchbruch in der allogenen Krebsimmuntherapie bedeutet
auf (Vaccines 2025 Jul 12;13(7):749; doi:10.3390/vaccines13070749) und hat zum ersten Mal gezeigt, dass aus CD34+ hämatopoetischen Stammzellen (HSC) gewonnene dendritische Zellen, die so verändert wurden, dass sie CD40L, CD93 und CXCL13 übermäßig produzieren, eine starke Anti-Tumor-Wirkung in humanisierten
More news about: Lunai Bioworks Inc.
Nov 07, 2025, 02:00 ET Lunai Bioworks logra la regresión completa de tumores pancreáticos primarios y metastásicos
doi:10.3390/vaccines13070749), que demostró por primera vez la potente actividad antitumoral de las células dendríticas (DC) derivadas de células madre hematopoyéticas (HSC) CD34+, modificadas genéticamente para sobreexpresar CD40L, CD93 y CXCL13 en modelos de ratón humanizados de cáncer de páncreas. Si bien el estudio inicial
More news about: Lunai Bioworks Inc.
Nov 06, 2025, 18:52 ET Lunai Bioworks 在臨床前人源化模型內，實現原發性和轉移性胰臟腫瘤的完全消退，標誌為同種異體癌症免疫療法的突破
這項新發表建基於 Lunai 的較早研究（Vaccines 2025 Jul 12;13(7):749; doi:10.3390/vaccines13070749），該研究首次在人源化胰腺癌小鼠體內證明，經過基因改造過度表達 CD40L、CD93 和 CXCL13 的 CD34+ 造血幹細胞 (HSC) 衍生的樹突狀細胞 (DC) 具備強大抗腫瘤活性。雖然最初研究採用研究級慢病毒載體，但最新報告描述一種最佳化兼符合臨床規範的構建體。該構建體保持同等療效，同時改進設計與製造特性，從而支持未來臨床轉化。 第二代構建體具備強大哺乳動物啟動子與已增強遺傳因子，從而驅動重要免疫調節份子的表達。Lunai
More news about: Lunai Bioworks Inc.
Nov 06, 2025, 02:00 ET Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
(Vaccines 2025 Jul 12;13(7):749; doi:10.3390/vaccines13070749), which first demonstrated potent anti-tumor activity of CD34+ hematopoietic stem cell (HSC)-derived DCs engineered to overexpress CD40L, CD93, and CXCL13 in humanized mouse models of pancreatic cancer. While the initial study utilized a research-grade
More news about: Lunai Bioworks Inc.
Nov 05, 2025, 09:22 ET Lunai Bioworks achieves complete regression of both primary and metastatic pancreatic tumors in preclinical humanized models, marking a breakthrough in allogeneic cancer immunotherapy
(Vaccines 2025 Jul 12;13(7):749; doi:10.3390/vaccines13070749), which first demonstrated potent anti-tumor activity of CD34+ hematopoietic stem cell (HSC)-derived DCs engineered to overexpress CD40L, CD93, and CXCL13 in humanized mouse models of pancreatic cancer. While the initial study utilized a research-grade
More news about: Lunai Bioworks Inc.
Oct 07, 2025, 09:00 ET Celaid Therapeutics Raises JPY 1.055 Billion (USD 7.2 Million) in the First Close of its Series B Financing
bottleneck of low HSC counts in cord blood with our proprietary HSC expansion technology, enabling us to provide HSCs with the best HLA type for the patient. CLD-001, the HLA best-matched and bone marrow-engrafting HSCs, is expected to significantly improve overall survival after HSC therapy.
More news about: Celaid Therapeutics Inc.
Oct 01, 2025, 07:05 ET Eminent Resumes Drilling on Its Emerging Gold Discovery in Nevada
encountered in Phase I (as released June 19, 2025). Hole HSC005 will test a key structural intersection between the Otis fault and the northwest-trending Little Humboldt fault (see Figures 3 and 4), originally defined by CSAMT geophysics. Hole HSC006 will be drilled from a new pad, oriented northwest to
More news about: Eminent Gold Corp.
Sep 16, 2025, 09:00 ET Air Premia Signs Long-Term Component Support Agreement with Lufthansa Technik for Boeing 787-9 Fleet
Korea, operates on the philosophy of being a "beloved airline that provides high-quality services with only the essentials" as a Hybrid Service Carrier (HSC) at reasonable prices. Since commencing its first international flights in July 2022, Air Premia has rapidly established
More news about: Air Premia